Drug Approval | June 06, 2024
Shilpa Biologicals files Type IV DMF of recombinant Human Albumin 20% with USFDA
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process
The state-of-the-art facility is equipped with best-in-class equipment and control systems
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
This significant achievement includes an initial order from GCPL valued at a substantial Rs. 2.4 crore
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Subscribe To Our Newsletter & Stay Updated
